Orna Therapeutics, Inc.

Sotio Biotech Inc.

Gregory Motz

Robert Alexander Wesselhoeft

Allen T Horhota

Junghoon Yang

Thomas Barnes

Amy M Becker

Kevin J Kauffman

Kathleen McGinness

Charles Wilson

Luke Barron

Michael Fray

Seth Ettenberg

Kathleen Mcginness

Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.

Lipid nanoparticle compositions for delivering circular polynucleotides

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof

Growing community of inventors

Cambridge, MA, United States of America

Gregory Motz